Treatments that target TGF-β signaling may be effective in multiple types of cancer, including pancreatic cancer, breast cancer, NSCLC, and glioma, more rigorous investigation in both preclinical and clinical settings is needed. This evidence concerns the gene TGFB1 and central nervous system cancer.